Ecalta

RSS

anidulafungin

Authorised
This medicine is authorised for use in the European Union.

Overview

Ecalta is used to treat patients from one month of age with invasive candidiasis (a fungal infection caused by a yeast called Candida). ‘Invasive’ means that the fungus has spread into the bloodstream.

Ecalta contains the active substance anidulafungin.

This EPAR was last updated on 15/12/2022

Authorisation details

Product details
Name
Ecalta
Agency product number
EMEA/H/C/000788
Active substance
anidulafungin
International non-proprietary name (INN) or common name
anidulafungin
Therapeutic area (MeSH)
Candidiasis
Anatomical therapeutic chemical (ATC) code
J02AX06
Publication details
Marketing-authorisation holder
Pfizer Europe MA EEIG
Revision
24
Date of issue of marketing authorisation valid throughout the European Union
20/09/2007
Contact address

Boulevard de la Plaine 17
1050 Bruxelles
Belgium

Product information

14/12/2022 Ecalta - EMEA/H/C/000788 - N/0051

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

 

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Antimycotics for systemic use

Therapeutic indication

Treatment of invasive candidiasis in adults and paediatric patients aged 1 month to < 18 years.

Assessment history

Related content

How useful was this page?

Add your rating